Filing Details
- Accession Number:
- 0001140361-23-001119
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-01-09 20:16:06
- Reporting Period:
- 2023-01-06
- Accepted Time:
- 2023-01-09 20:16:06
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1746473 | Pliant Therapeutics Inc. | PLRX | Pharmaceutical Preparations (2834) | 474272481 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1808895 | Bernard Coulie | C/O Pliant Therapeutics, Inc. 260 Littlefield Avenue South San Francisco CA 94080 | President And Ceo | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-01-06 | 15,000 | $2.08 | 108,812 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-01-06 | 15,000 | $19.04 | 93,812 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2023-01-09 | 5,000 | $2.08 | 98,812 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-01-09 | 5,000 | $19.17 | 93,812 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2023-01-06 | 15,000 | $0.00 | 15,000 | $2.08 |
| Common Stock | Stock Option (right to buy) | Disposition | 2023-01-09 | 5,000 | $0.00 | 5,000 | $2.08 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 252,380 | 2029-01-23 | No | 4 | M | Direct | |
| 247,380 | 2029-01-23 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 449,317 | Indirect | See footnote |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.17, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.50, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
- Shares held by The Coulie/Leyman Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- 1/48th of the shares subject to the original option grant vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date.
Billionaire Hedge Funds
